CL2011000270A1 -
Individual oral dosage form in the form of a water-soluble thin film matrix (thickness equal to or less than 300 um) comprising a water soluble matrix polymer and particles of size d90 less than 280 um comprising a progestin and an agent protective, useful in the inhibition of ovulation.
- Google Patents
Individual oral dosage form in the form of a water-soluble thin film matrix (thickness equal to or less than 300 um) comprising a water soluble matrix polymer and particles of size d90 less than 280 um comprising a progestin and an agent protective, useful in the inhibition of ovulation.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=66221450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000270(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AGfiledCriticalBayer Pharma AG
Publication of CL2011000270A1publicationCriticalpatent/CL2011000270A1/en
Forma de dosificación individual que comprende matriz de película delgada soluble en agua que comprende al menos un polímero de matriz soluble en agua y partículas que comprenden al menos una progestina y al menos un agente protector, con tamaño de partícula D90<<280 um y la matriz de película tiene grosor <<=300 um.Individual dosage form comprising water soluble thin film matrix comprising at least one water soluble matrix polymer and particles comprising at least one progestin and at least one protective agent, with particle size D90 << 280 um and the film matrix has thickness << = 300 um.
CL2011000270A2008-08-082011-02-08
Individual oral dosage form in the form of a water-soluble thin film matrix (thickness equal to or less than 300 um) comprising a water soluble matrix polymer and particles of size d90 less than 280 um comprising a progestin and an agent protective, useful in the inhibition of ovulation.
CL2011000270A1
(en)
Individual oral dosage form in the form of a water-soluble thin film matrix (thickness equal to or less than 300 um) comprising a water soluble matrix polymer and particles of size d90 less than 280 um comprising a progestin and an agent protective, useful in the inhibition of ovulation.
An aqueous composition containing bromhexine, wherein the composition has an amount of sugar-alcohols less than 10 g based on 100 ml of the composition; and its use for secretory therapy in acute and chronic bronchopulmonary diseases.
Bio-film formation resistant material comprising an active agent consisting essentially of an insoluble copper oxide at a concentration of between 3 and 10% of said bio-film formation resistant material; and prevention method, reduction in incidence of biofilm formation.
Compound 4- [5 (2-amino-ethanesulfonyl) -isoquinolin-7-yl] -phenolo a pharmaceutically acceptable salt or a hydrate or salt thereof; pharmaceutical composition comprising said compound, lyophilized pharmaceutical composition; and use of the compound as antineiplasic and / or antiviral.
Individual oral dosage form in the form of a water-soluble thin film matrix (thickness equal to or less than 300 um) comprising a water soluble matrix polymer and particles of size d90 less than 280 um comprising a progestin and an agent protective, useful in the inhibition of ovulation.
Unit dosage form comprising a thin film matrix comprising a water soluble matrix polymer and 10 to 200 ug of estradiol, or a hydrate or an ester, with a thickness less than 300 um, useful in a physical condition. caused by insufficient endogenous levels of estrogens.